MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY

Main Article Content

Francesco Lococo *
Roberto Latagliata
Massimo Breccia
(*) Corresponding Author:
Francesco Lococo | francesco.lo.coco@uniroma2.it

Abstract

Unlike other forms of AML, APL is less frequently diagnosed in the elderly and has a relatively favourable outcome. Elderly patients with APL seem at least as responsive to therapy as do younger patients, but rates of response and survival are lower in this age setting owing to a higher incidence of early deaths and deaths in remission when conventional treatment with ATRA and chemotherapy is used. Elderly APL patients are more likely to present with low-risk features compared with younger patients, and this may explain the relative low risk of relapse reported in several clinical studies. Alternative approaches, such as arsenic trioxide and gentuzumab ozogamicin have been tested with success in this setting and could replace in the near future frontline conventional chemotherapy and ATRA.


Downloads month by month

Downloads

Download data is not yet available.

Article Details